Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Total Current Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Total Current Liabilities for 6 consecutive years, with $18.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 48.01% to $18.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.7 million, a 48.01% decrease, with the full-year FY2025 number at $18.7 million, down 48.01% from a year prior.
  • Total Current Liabilities was $18.7 million for Q4 2025 at TScan Therapeutics, down from $29.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $38.6 million in Q2 2024 to a low of $14.0 million in Q1 2023.
  • A 5-year average of $25.8 million and a median of $28.7 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 124.1% in 2024, then crashed 48.01% in 2025.
  • TScan Therapeutics' Total Current Liabilities stood at $21.3 million in 2021, then dropped by 18.92% to $17.3 million in 2022, then soared by 72.32% to $29.8 million in 2023, then increased by 20.58% to $36.0 million in 2024, then plummeted by 48.01% to $18.7 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Total Current Liabilities are $18.7 million (Q4 2025), $29.2 million (Q3 2025), and $31.3 million (Q2 2025).